- Home
- APLS
as 07-26-2024 4:00pm EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Upcoming Earnings Alert:
Get ready for potential market movements as Apellis Pharmaceuticals Inc. APLS prepares to release earnings report on 01 Aug 2024.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 4.3B | IPO Year: | 2017 |
| Target Price: | $72.24 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.83 - $73.80 | Next Earning Date: | 08-01-2024 |
| Revenue: | $524,070,000 | Revenue Growth: | 394.93% |
| Revenue Growth (this year): | 110.66% | Revenue Growth (next year): | 44.47% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunlop A. Sinclair | APLS | Director | Jun 21 '24 | Sell | $39.63 | 1,695 | $67,172.85 | 136,998 | SEC Form 4 |
| Dunlop A. Sinclair | APLS | Director | Jun 21 '24 | Sell | $39.22 | 35,305 | $1,384,662.10 | 138,693 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | May 8 '24 | Sell | $42.15 | 56,335 | $2,374,542.78 | 1,138,555 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | May 8 '24 | Sell | $42.85 | 22,472 | $962,902.73 | 1,116,083 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | May 8 '24 | Sell | $44.03 | 100 | $4,402.50 | 1,115,983 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Apr 8 '24 | Sell | $54.12 | 64,379 | $3,483,966.15 | 1,120,711 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Apr 8 '24 | Sell | $54.92 | 4,728 | $259,639.07 | 1,115,983 | SEC Form 4 |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Apr 1 '24 | Sell | $58.66 | 4,000 | $234,640.00 | 93,338 | SEC Form 4 |
| Dunlop A. Sinclair | APLS | Director | Mar 19 '24 | Sell | $57.18 | 18,681 | $1,068,160.90 | 173,998 | SEC Form 4 |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Mar 18 '24 | Sell | $56.90 | 9,913 | $564,049.70 | 54,693 | SEC Form 4 |
| Chopas James George | APLS | VP/Chief Accounting Officer | Mar 15 '24 | Sell | $56.46 | 184 | $10,388.82 | 38,883 | SEC Form 4 |
| Nicholson Nur | APLS | Chief Technical Officer | Mar 13 '24 | Sell | $57.31 | 7,768 | $445,160.78 | 59,739 | SEC Form 4 |
| Nicholson Nur | APLS | Chief Technical Officer | Mar 13 '24 | Sell | $58.13 | 3,452 | $200,676.84 | 56,287 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Mar 8 '24 | Sell | $61.88 | 42,750 | $2,645,173.35 | 1,142,340 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Mar 8 '24 | Sell | $62.69 | 26,257 | $1,646,040.83 | 1,116,083 | SEC Form 4 |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Mar 8 '24 | Sell | $63.35 | 100 | $6,335.00 | 1,115,983 | SEC Form 4 |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Mar 1 '24 | Sell | $62.86 | 4,000 | $251,440.00 | 95,338 | SEC Form 4 |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Mar 1 '24 | Sell | $63.95 | 2,000 | $127,900.00 | 93,338 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Mar 1 '24 | Sell | $62.21 | 28,868 | $1,795,964.88 | 534,794 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Mar 1 '24 | Sell | $62.96 | 41,704 | $2,625,813.12 | 493,090 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Mar 1 '24 | Sell | $64.26 | 62,503 | $4,016,274.02 | 430,587 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Mar 1 '24 | Sell | $64.92 | 116,512 | $7,563,527.95 | 314,075 | SEC Form 4 |
| Francois Cedric | APLS | Chief Executive Officer | Mar 1 '24 | Sell | $65.68 | 413 | $27,125.84 | 313,662 | SEC Form 4 |
| Watson David O. | APLS | General Counsel | Feb 12 '24 | Sell | $67.77 | 781 | $52,925.95 | 103,390 | SEC Form 4 |
| Townsend Adam J. | APLS | Chief Commercial Officer | Feb 12 '24 | Sell | $67.77 | 1,148 | $77,796.40 | 92,453 | SEC Form 4 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
GlobeNewswire
9 days ago
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
GlobeNewswire
18 days ago
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Zacks
21 days ago
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Zacks
25 days ago
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
MT Newswires
a month ago
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
MT Newswires
a month ago
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $49 From $52, Maintains Neutral Rating
MT Newswires
a month ago
Update: Apellis Pharmaceuticals Shares Fall After Announcing Plan to Seek Re-Examination of Negative CHMP Opinion on Pegcetacoplan for Geographic Atrophy
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.